Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platformsnews2022-04-19T20:29:14+00:00April 19th, 2022|FierceBiotech|
BioXcel will use $260M finance deal to expand indications for schizophrenia drugnews2022-04-19T19:57:03+00:00April 19th, 2022|FierceBiotech|
Finch’s nest thins out with 20% of employees cut in restructuring after FDA holdnews2022-04-19T13:54:46+00:00April 19th, 2022|FierceBiotech|
Imara eliminates 83% of workforce—including chief medical officer—in wake of pipeline wipeoutnews2022-04-19T13:54:36+00:00April 19th, 2022|FierceBiotech|
Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisitionnews2022-04-19T13:07:36+00:00April 19th, 2022|FierceBiotech|
Axsome moves ‘closer to judgement day’ for stalled depression therapynews2022-04-19T12:54:48+00:00April 19th, 2022|FierceBiotech|
Moderna’s bivalent beta booster betters Spikevax versus omicron, pointing to promise of variant-specific jabsnews2022-04-19T12:09:12+00:00April 19th, 2022|FierceBiotech|
Ouch! Acadia’s non-opioid painkiller flunks midphase test, weakening a potential rival to Vertexnews2022-04-19T08:38:20+00:00April 19th, 2022|FierceBiotech|
Sionna unveils with $111M series B to pursue quest for ‘holy grail’ cystic fibrosis targetnews2022-04-19T05:41:20+00:00April 19th, 2022|FierceBiotech|
Fore tees up new CEO, 5 months after ousting former chief executive on insider trading chargesnews2022-04-18T15:27:17+00:00April 18th, 2022|FierceBiotech|
